OCGN logo

OCUGEN INC

OCGNNASDAQ
🏆 #3254 by market capEarnings Nov 3US Equity
$1.09▲ $0.06 (+5.31%)
Market closed · at close
🔔
Track OCGN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.3%
7d▲ 8.5%
14d▲ 7.4%
30d▼ 17.4%
ytd▼ 18.7%
1y▼ 33.1%
🏦Market Cap
$370M
Small Cap
📈Revenue Growth (YoY)
+8.8%
Slowing
📊Gross Margin
100.0%
High
💵FCF Margin
-1340.1%
Thin
⚖️P/S Ratio
76.3x
Expensive
Otter Score
76
Good

Trading Snapshot

Day Range
$1.08 – $1.10
52-Week Range
$0.97 – $2.73
Volume
$2.12B
Avg Volume
$1.92B
Shares Outstanding
339.1M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
-4.1
P/S Ratio
76.3x
EPS (TTM)
$-0.24
Dividend Yield
0.00%
Dilution (1yr)
+7.4%

Why Investors Own OCGN

  • ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 46% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OCGN logo

OCUGEN INC

OCGN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▲ +8.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
45.9%▼ −10.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$63M▲ +14.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$57M▲ +25.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
312.3M▲ +7.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$15M▼ −$41M YoY
StockOtter · stockotter.space

About OCUGEN INC

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$1.11
▲ +1.4% Upside
High Target$1.35
Low Target$0.95
Based on 28 analysts

Latest News & Updates

🚀
Reuters·2h ago

OCUGEN INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift OCGN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

OCUGEN INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.